ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,737.65
      0.38%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Apellis Pharmaceuticals Inc (APLS)

      7. Apellis Pharmaceuticals Inc (APLS) News

      APLS

      Apellis Pharmaceuticals (APLS)

      Apellis Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:APLS
      DateTimeSourceHeadlineSymbolCompany
      05/24/202410:00AMGlobeNewswire Inc.Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA CongressNASDAQ:APLSApellis Pharmaceuticals Inc
      05/21/20244:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      05/14/20248:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
      05/14/20248:00AMGlobeNewswire Inc.Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetNASDAQ:APLSApellis Pharmaceuticals Inc
      05/09/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      05/08/20245:13PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      05/07/20247:05AMGlobeNewswire Inc.Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
      05/07/20247:02AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLSApellis Pharmaceuticals Inc
      05/06/20247:00AMGlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
      05/01/20247:00AMGlobeNewswire Inc.Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingNASDAQ:APLSApellis Pharmaceuticals Inc
      04/26/20247:15AMGlobeNewswire Inc.Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)NASDAQ:APLSApellis Pharmaceuticals Inc
      04/23/20247:00AMGlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
      04/04/20244:05PMGlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
      04/01/20247:00AMGlobeNewswire Inc.Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:APLSApellis Pharmaceuticals Inc
      03/11/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      03/11/20247:00AMGlobeNewswire Inc.Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina AdvisorNASDAQ:APLSApellis Pharmaceuticals Inc
      03/08/20244:10PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      03/08/20247:45AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      03/06/20244:05PMGlobeNewswire Inc.Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:APLSApellis Pharmaceuticals Inc
      03/05/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      03/05/20244:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      03/01/20244:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      03/01/20241:37PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLSApellis Pharmaceuticals Inc
      02/29/20245:10PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:APLSApellis Pharmaceuticals Inc
      02/27/20247:35AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APLSApellis Pharmaceuticals Inc
      02/27/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLSApellis Pharmaceuticals Inc
      02/27/20247:05AMGlobeNewswire Inc.Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
      02/27/20247:01AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLSApellis Pharmaceuticals Inc
      02/26/20247:00AMGlobeNewswire Inc.Apellis Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:APLSApellis Pharmaceuticals Inc
      02/20/20247:00AMGlobeNewswire Inc.Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APLSApellis Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:APLS